
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August 2020

Commission File Number: 001-38067

Verona Pharma plc
(Translation of registrant's name into English)

3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Notification of Major Holdings TR-1 announcements (each a "TR-1 Announcement")

On July 24, 2020 Novo Holdings A/S notified Verona Pharma plc (the "Company") using a Form TR-1 that its voting rights in the Company have crossed the 6 % threshold following the recent equity financing by the Company. The Novo TR-1 Announcement is furnished herewith as Exhibit 1.1 to this Report on Form 6-K.

On July 30, 2020 Abingworth LLP and Abingworth Bioventures VI LP notified the Company using a Form TR-1 that its voting rights in the Company have crossed the 5% threshold following the recent equity financing by the Company. The Abingworth TR-1 Announcement is furnished herewith as Exhibit 1.2 to this Report on Form 6-K.

On August 6, 2020 Growth Equity Opportunities Fund IV, LLC and Growth Equity Opportunities 17, LLC notified the Company using a Form TR-1 of its voting rights in the Company following the recent equity financing by the Company. The Growth Equity Opportunities TR-1 Announcement is furnished herewith as Exhibit 1.3 to this Report on Form 6-K.

Person Discharging Managerial Responsibilities ("PDMR") announcement (the "PDMR Announcement")

On August 4, 2020, the Company issued a press release reporting the issuance to Dr David Zaccardelli, CEO, and Mr Mark Hahn, CFO of the Company, an aggregate of 267,296 ordinary shares of 5 pence each ("Ordinary Shares"), represented by 33,412 American Depositary Shares ("ADSs"), following the vesting of previously granted Restricted American Depositary Share Units ("RADSUs"), and the disposal by them of an aggregate of 70,120 Ordinary Shares (represented by 8,765 ADSs) under 10b5-1 plans established for the purpose of selling ADSs to cover tax withholding requirements on vested RADSUs.

The PDMR Announcement is furnished herewith as Exhibit 1.4 to this Report on Form 6-K.

EXHIBIT INDEX

Exhibit No.	Description
1.1	Novo TR-1 Announcement
1.2	Abingworth TR-1 Announcement
1.3	Growth Equity Opportunities TR-1 Announcement
1.4	PDMR Announcement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: August 10, 2020

By: /s/ Claire Poll

Name: Claire Poll

Title: Legal Counsel

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:		Verona Pharma plc		
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)				
Non-UK issuer				<input type="checkbox"/>
2. Reason for the notification (please mark the appropriate box or boxes with an "X")				
An acquisition or disposal of voting rights				<input checked="" type="checkbox"/>
An acquisition or disposal of financial instruments				<input type="checkbox"/>
An event changing the breakdown of voting rights				<input type="checkbox"/>
Other (please specify) ⁱⁱⁱ :				<input type="checkbox"/>
3. Details of person subject to the notification obligation^{iv}				
Name		Novo Holdings A/S		
City and country of registered office (if applicable)				
4. Full name of shareholder(s) (if different from 3.) ^v				
Name				
City and country of registered office (if applicable)				
5. Date on which the threshold was crossed or reached^{vi}:		July 22, 2020		
6. Date on which issuer notified (DD/MM/YYYY):		July 22, 2020		
7. Total positions of person(s) subject to the notification obligation				
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights of issuer ^{vii}
Resulting situation on the date on which threshold was crossed or reached	5.1364%		5.1364%	414,278,294
Position of previous notification (if applicable)				

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^{viii}				
A: Voting rights attached to shares				
Class/type of shares ISIN code (if possible)	Number of voting rights ^{ix}		% of voting rights	
	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary Shares (0.1p) GB00B06GSH43	6,464,065		1.5603%	
ADSS US9250501064	14,814,808		3.5761%	
SUBTOTAL 8. A	21,278,873		5.1364%	

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
SUBTOTAL 8. B 1				

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))					
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Physical or cash settlement ^{xii}	Number of voting rights	% of voting rights
SUBTOTAL 8.B.2					

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")			
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^{xiii}			X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^{xiv} (please add additional rows as necessary)			
Name ^{xv}	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information ^{xvi}

Place of completion	Outside a trading venue
Date of completion	22 July 2020

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:		Verona Pharma plc		
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)				
Non-UK issuer				<input type="checkbox"/>
2. Reason for the notification (please mark the appropriate box or boxes with an "X")				
An acquisition or disposal of voting rights				<input checked="" type="checkbox"/>
An acquisition or disposal of financial instruments				<input type="checkbox"/>
An event changing the breakdown of voting rights				<input type="checkbox"/>
Other (please specify) ⁱⁱⁱ :				<input type="checkbox"/>
3. Details of person subject to the notification obligation^{iv}				
Name		Abingworth LLP Abingworth Bioventures VI LP		
City and country of registered office (if applicable)		London, UK		
4. Full name of shareholder(s) (if different from 3.) ^v				
Name		State Street (Nominees) Limited (as nominee for Abingworth Bioventures VI LP)		
City and country of registered office (if applicable)		London, UK		
5. Date on which the threshold was crossed or reached^{vi}:		22/07/2020		
6. Date on which issuer notified (DD/MM/YYYY):		30/07/2020		
7. Total positions of person(s) subject to the notification obligation				
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights of issuer ^{vii}
Resulting situation on the date on which threshold was crossed or reached	4.75		4.75	414,278,294
Position of previous notification (if applicable)	6.90		6.90	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^{viii}

A: Voting rights attached to shares				
Class/type of shares ISIN code (if possible)	Number of voting rights ^{ix}		% of voting rights	
	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Verona Pharma plc GB00BYW2KH80 5p Ords	1		less than 0.01	
Verona Pharma plc US9250501064 ADSS	19,660,000		4.75	
SUBTOTAL 8. A	19,660,001		4.75	

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
SUBTOTAL 8. B 1				

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))					
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Physical or cash settlement ^{xii}	Number of voting rights	% of voting rights
SUBTOTAL 8.B.2					

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")			
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^{xiii}			
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^{xiv} (please add additional rows as necessary)			X
Name ^{xv}	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Abingworth LLP	4.75		4.75
Abingworth Bioventures VI LP	less than 0.01		less than 0.01

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information^{xvi}
Abingworth Bioventures VI LP (which holds 19,660,001 shares in the company (4.75%)) is managed by Abingworth LLP.

Place of completion	Outside a trading venue
Date of completion	30 July 2020

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:		Verona Pharma plc		
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)				
Non-UK issuer				<input type="checkbox"/>
2. Reason for the notification (please mark the appropriate box or boxes with an "X")				
An acquisition or disposal of voting rights				<input checked="" type="checkbox"/>
An acquisition or disposal of financial instruments				<input type="checkbox"/>
An event changing the breakdown of voting rights				<input checked="" type="checkbox"/>
Other (please specify) ⁱⁱⁱ :				<input type="checkbox"/>
3. Details of person subject to the notification obligation^{iv}				
Name		Growth Equity Opportunities Fund IV, LLC Growth Equity Opportunities 17, LLC		
City and country of registered office (if applicable)		Delaware, United States		
4. Full name of shareholder(s) (if different from 3.) ^v				
Name				
City and country of registered office (if applicable)				
5. Date on which the threshold was crossed or reached^{vi}:		22/07/2020		
6. Date on which issuer notified (DD/MM/YYYY):		06/08/2020		
7. Total positions of person(s) subject to the notification obligation				
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights of issuer ^{vii}
Resulting situation on the date on which threshold was crossed or reached	9.86% (Aggregated - see Section 11)	N/A	9.86% (Aggregated - see Section 11)	414,545,590
Position of previous notification (if applicable)	9.86%	N/A	9.86%	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^{viii}				
A: Voting rights attached to shares				
Class/type of shares ISIN code (if possible)	Number of voting rights ^{ix}		% of voting rights	
	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
ADSS US9250501064	40,868,504 (Aggregated - see Section 11)		9.86% (Aggregated - see Section 11)	
SUBTOTAL 8. A	40,868,504		9.86%	

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
N/A				
SUBTOTAL 8. B 1				

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))					
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Physical or cash settlement ^{xii}	Number of voting rights	% of voting rights
N/A					
SUBTOTAL 8.B.2					

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^{xiii}

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^{xiv} (please add additional rows as necessary) X

Name ^{xv}	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
NEA 15 GP, LLC, a limited liability company formed in the State of Delaware, is the general partner of NEA Partners 15, L.P.			
NEA Partners 15, L.P., a limited partnership formed in the State of Delaware, is the general partner of New Enterprise Associates 15, L.P.			
New Enterprise Associates 15, L.P., a limited partnership formed in the State of Delaware, is sole member of Growth Equity Opportunities Fund IV, LLC			
Growth Equity Opportunities Fund IV, LLC is a limited liability company formed in the State of Delaware, United States	2.35%	N/A	2.35%
NEA 17 GP, LLC, a limited liability company formed in the State of Delaware, is the general partner of NEA Partners 17, L.P.			
NEA Partners 17, L.P., a limited partnership formed in the State of Delaware, is the general partner of New Enterprise Associates 17, L.P.			
New Enterprise Associates 17, L.P., a limited partnership formed in the State of Delaware, is sole member of Growth Equity Opportunities 17, LLC			

Growth Equity Opportunities 17, LLC is a limited liability company formed in the State of Delaware, United States	7.51%		7.51%
---	-------	--	-------

10. In case of proxy voting, please identify:

Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information^{xvi}

Growth Equity Opportunities 17, LLC purchased 3,888,889 American Depositary Shares (ADSs), representing 31,111,112 Ordinary Shares, from the Issuer on 22 July 2020 as part of the Issuer's capital raising (the "Financing") which comprised the issuance of ADSs and Ordinary Shares.

Growth Equity Opportunities Fund IV, LLC did not participate in the Financing and so continues to hold 1,219,674 ADSs representing 9,757,392 Ordinary Shares, as previously reported on its TR-1 filed on 8 May 2017.

Growth Equity Opportunities Fund IV, LLC (which holds 2.35% voting rights) and Growth Equity Opportunities 17, LLC (which holds 7.51% of voting rights) are acting in concert for the purposes of DTR 5.2.1R(a), consequently their respective holdings are deemed to be aggregated to 9.86% in total.

Overall, there has been no increase or decrease from the 9 to 10% voting right threshold that was reported in the previous TR-1 filing of 8 May 2017. However, as explained in this Section 11 there have been changes in the breakdown of how the voting rights are held. It is on this basis that this TR-1 has been completed.

Place of completion	USA
Date of completion	7 August, 2020



Verona Pharma

Issue of Equity, PDMR Dealings & Total Voting Rights

LONDON, UK, and RALEIGH, NC, August 4, 2020 – Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, notifies the following transactions by persons discharging managerial responsibilities (“PDMRs”).

Issue of Equity

An aggregate of 267,296 ordinary shares of 5 pence each (“Ordinary Shares”), represented by 33,412 American Depositary Shares (“ADSs”) following the vesting on July 31, 2020 of previously granted Restricted American Depositary Share Units (“RADSUs”) have been issued to Dr David Zaccardelli, CEO, and Mr Mark Hahn, CFO, of the Company (the “New ADSs”). One ADS represents eight ordinary shares of the Company (“Ordinary Shares”).

As announced on March 5, 2020, RADSUs were granted to Dr Zaccardelli and Mr Hahn pursuant to their employment agreements as payment in lieu of a portion of their annual base salaries. The New ADSs, of which 22,275 (representing 178,200 Ordinary Shares) are issued to Dr Zaccardelli and 11,137 (representing 89,096 Ordinary Shares) are issued to Mr Hahn, represent the second of four installments of these RADSUs to vest with respect to their annual base salaries.

Disposal of ADSs

An aggregate of 70,120 Ordinary Shares (represented by 8,765 ADSs) were sold on July 31, 2020 under 10b5-1 plans established on May 11, 2020 by Dr Zaccardelli and Mr Hahn for the purpose of selling ADSs to cover tax withholding requirements on vested RADSUs.

Dr Zaccardelli sold 5,424 ADSs (representing 43,392 Ordinary Shares) at an average price per ADS of \$6.7211. Mr Hahn sold 3,341 ADSs (representing 26,728 Ordinary Shares) at an average price per ADS of \$6.7229.

Following the above transactions, Dr Zaccardelli will have an interest in the Company of 94,680 ADSs, representing 757,440 Ordinary Shares, or 0.18% of the Company’s total voting rights, and Mr Hahn will have an interest in the Company of 41,156 ADSs, representing 329,248 Ordinary Shares, or 0.08% of the Company’s total voting rights.

The notification of dealing form in respect of the transactions for each PDMR can be found below.

Total Voting Rights

Application has been made to the London Stock Exchange for the 267,296 Ordinary Shares represented by the New ADRs to be admitted to trading on AIM, with dealings expected to commence at 0800 BST, August 10, 2020 ("Admission").

The Company's issued share capital is 462,634,486. Following Admission, the Company will have a total of 414,545,590 Ordinary Shares in issue each carrying one voting right, and 48,088,896 non-voting Ordinary Shares not admitted to trading. The Company does not hold any Ordinary Shares in treasury.

The figure of 414,545,590 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information, please contact:

Verona Pharma plc

David Zaccardelli, Chief Executive Officer

Victoria Stewart, Director of Communications

Tel: +44 (0)20 3283 4200

info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)

Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance)

Tom Salvesen (Corporate Broking)

Tel: +44 (0)20 7496 3000

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Dr David Zaccardelli
2	Reason for the notification	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Verona Pharma plc
b)	Legal Entity Identifier	213800EVI6O6J3TIAL06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	American Depositary Shares ("ADSs"), each representing 8 Ordinary Shares.
	Identification code	ISIN Code: US9250501064

b)	Nature of the transaction	David Zaccardelli was issued 178,200 Ordinary Shares following the vesting of 22,275 Restricted American Depositary Units ("RADSUs") as payment in lieu of base salary, each representing 8 Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s) (ADSs)
		No consideration paid	22,275 RADSUs (representing 178,200 Ordinary Shares)
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	31 July 2020	
f)	Place of the transaction	London Stock Exchange, AIM	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	American Depositary Shares ("ADSs"), each representing 8 Ordinary Shares.	
	Identification code	ISIN Code: US9250501064	
b)	Nature of the transaction	Disposal of ADSs pursuant to a 10b5-1 plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s) (ADSs)
		\$6.56	285
		\$6.57	15
		\$6.59	200
		\$6.60	200
		\$6.61	300
		\$6.62	200
		\$6.63	200
		\$6.65	300
		\$6.66	100
		\$6.67	400
		\$6.68	100
		\$6.69	100
		\$6.70	100
		\$6.72	696
		\$6.73	103
		\$6.74	200
		\$6.75	323
		\$6.78	576
		\$6.79	226
		\$6.80	100
\$6.81	100		
\$6.88	100		
\$6.91	100		
\$6.96	100		
\$7.00	130		
\$7.03	100		
\$7.04	70		

d)	Aggregated information	
	- Aggregated volume	Aggregated volume: 5,424,ADSs
	- Price	Average price \$6.7211
e)	Date of the transaction	31 July 2020
f)	Place of the transaction	NASDAQ

l

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Mark Hahn	
2	Reason for the notification		
a)	Position/status	Chief Financial Officer	
b)	Initial notification /Amendment	Initial Notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Verona Pharma plc	
b)	Legal Entity Identifier	213800EVI6O6J3TIAL06	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	American Depositary Shares ("ADSs"), each representing 8 Ordinary Shares.	
	Identification code	ISIN Code: US9250501064	
b)	Nature of the transaction	Mark Hahn was issued 89,096 Ordinary Shares following the vesting of 11,137 Restricted American Depositary Units ("RADSUs") as payment in lieu of base salary, each representing 8 Ordinary Shares	
c)	Price(s) and volume(s)	Price (s)	Volumes(s) ADSs
		No consideration paid	11,137 RADSUs (representing 89,096 Ordinary Shares)
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	31 July 2020	
f)	Place of the transaction	London Stock Exchange, AIM	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	American Depositary Shares ("ADSs"), representing 8 Ordinary Shares.	
	Identification code	ISIN Code: US9250501064	
b)	Nature of the transaction	Sale of ADSs pursuant to a 10b5-1 plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s) (ADSs)
		\$6.56	102

	\$6.57	8
	\$6.58	55
	\$6.59	120
	\$6.61	100
	\$6.62	100
	\$6.63	200
	\$6.65	200
	\$6.66	100
	\$6.67	300
	\$6.68	100
	\$6.70	284
	\$6.71	12
	\$6.72	104
	\$6.73	201

|

		\$6.74	100
		\$6.75	200
		\$6.76	100
		\$6.78	265
		\$6.81	100
		\$6.82	100
		\$6.85	100
		\$7.00	200
		\$7.03	100
d)	Aggregated information		
	- Aggregated volume	Aggregated volume: 3,341 ADSs	
	- Aggregated price	Average price: \$6.7229	
e)	Date of the transaction	31 July 2020	
f)	Place of the transaction	NASDAQ	

I